An Expert Provides Insight Into the Use of BTK Inhibitors in CLL
Parameswaran Venugopal, MD, discussed the toxicity profiles of BTK inhibitors regarding treatment selection in CLL.
BTK Combos Seek to Raise the Bar in CLL Treatment Paradigm
Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.
BTK Inhibitor Combos Could Transform the Complex CLL Armamentarium
Alan P. Z. Skarbnik, MD, breaks down factors that should be kept in mind when navigating the complex chronic lymphocytic leukemia armamentarium as it relates to BTK inhibitors.
Dr. Awan on the Importance of Risk Stratification in CLL
Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.
Novel Agents Capture Attention in Newly Diagnosed CLL/SLL
Matthew Lunning, DO, discussed other key considerations for choosing treatments, continuous vs fixed-duration therapies, and emerging agents for patients with relapsed/ refractory CLL and SLL.
Dr. Danilov on the Role of Disease Biology in Up-front Treatment Selection in CLL
Alexey V. Danilov, MD, PhD, discusses the role of disease biology in up-front treatment selection in chronic lymphocytic leukemia.
Dr. Lunning on Initial Treatment Considerations in CLL
Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.
Treatment Selection in CLL Broadens Beyond Discussions of Efficacy
Alexey V. Danilov, MD, PhD, discusses BTK inhibitors and BCL-2 inhibitors that have led to a paradigm shift in the treatment of patients with chronic lymphocytic leukemia.
Dr. Awan on the Importance of Collaborative Care in CLL
Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.
Dr. Danilov on the Role of Chemoimmunotherapy in CLL
Alexey V. Danilov, MD, PhD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.
Dr. Awan on Treatment Options in the First Relapsed Setting of CLL
Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512